Abstract
As a member of the epidermal growth factor receptor family (EGFR) of receptor tyrosine kinases, ERBB3 plays an important role in mediating cellular growth and differentiation. Recent research works identified that CD74-NRG1 fusions lead to overexpression of the EGF-like domain of NRG1, and thus activate ERBB3 and PI3K-AKT signaling pathways. The fusion was detected in lung adenocarcinomas, and served as an important oncogenic factor for ERBB3 driven cancers. A sequential virtual screening strategy has been applied to ERBB3 crystal structure using databases of natural products and Chinese traditional medicine compounds, and led to identification of a group of small molecular compounds potentially capable of blocking ERBB3. Six small molecular compounds were selected for in vitro analysis. Five of these molecules significantly inhibited the growth of A549 cells. Among them, compound VS1 is the most promising one with IC50 values of 269.75 μM, comparing to the positive control of nimustine hydrochloride with IC50 values of 264.14 μM. With good specificity and predicted ADMET results, our results support the feasibility by using a pharmacophore of the compound VS1 for designing and optimization of ERBB3 inhibitors.
Similar content being viewed by others
Reference
Gridelli C, Perrone F, Monfardini S (1997) Lung cancer in the elderly. Eur J Cancer 33(14):2313–2314
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
da Cunha Santos G, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol: Mech Dis 6:49–69
Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S (2010) Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16(1):291–303. doi:10.1158/1078-0432.CCR-09-1660
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Waterfield MD (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307(5951):521–527
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312(5994):513–516
Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 86(23):9193–9197
Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Shoyab M (1993) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A 90(5):1746–1750
Liu P, Cleveland TE, Bouyain S, Byrne PO, Longo PA, Leahy DJ (2012) A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci 109(27):10861–10866
Cho H, Leahy D (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297(5585):1330–1333
Falls DL (2003) Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284(1):14–30
Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Kohno T (2014) Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 20(12):3087–3093. doi:10.1158/1078-0432.CCR-14-0107
Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Thomas RK (2014) CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4(4):415–422. doi:10.1158/2159-8290.CD-13-0633
Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19(3):183–232
Arteaga CL, Engelman JA (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282–303. doi:10.1016/j.ccr.2014.02.025
Schoeberl B, Pace EA, Fitzgerald JB et al (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor–PI3K axis. Sci Signal 2(77):ra31
Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Arteaga CL (2013) Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 73(19):6013–6023
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Lugovskoy AA (2014) MM-141, an IGF-IR–and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 13(2):410–425
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Nielsen UB (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11(3):582–593
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Wong A (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711
Patridge E, Gareiss P, Kinch MS, Hoyer D (2015) An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today 21:204–207
Tang JL, Liu BY, Ma KW (2008) Traditional Chinese medicine. Lancet 372(9654):1938–1940
Clardy J, Walsh C (2004) Lessons from natural molecules. Nature 432:829–837
O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open babel: an open chemical toolbox. J Cheminf 3:33. doi:10.1186/1758-2946-3-33
Xinrui S, Da L, Jie C, Yong Z (2014) Computer aided drug screening platform and its application. Chinese J Bioinform 12(4)
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461
Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee PW, Tang Y (2012) admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties. J Chem Inf Model 52(11):3099–3105
Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072
Cheng F, Li W, Zhou Y, Li J, Shen J, Leea PW, Tang Y (2013) Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). Mol BioSyst 9:1316–1325
Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42(D1):D1091–D1097
Tosh DK, Padia J, Salvemini D, Jacobson KA (2015) Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signal 11(3):371–387
Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K, Watanabe M (1999) A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 36(2):47–50
Miyamoto T, Min W, Lillehoj HS (2002) Lymphocyte proliferation response during Eimeria tenella infection assessed by a new, reliable, nonradioactive colorimetric assay. Avian Dis 46(1):10–16
Weisel M, Proschak E, Schneider G (2007) PocketPicker: analysis of ligand binding-sites with shape descriptors. Chem Cent J 1:7
Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Ettenberg SA (2013) An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 73(19):6024–6035
Beijing Computing Center-the Department of Computational Medicine-Computer aided drug screening platform (n.d.). Retrieved from http://www.vslead.com/
Mitsuhashi Y, Lnaba M, Sugiyama Y, Kohayashi T (1992) In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase‐nonspecific agents under the clinically equivalent area under the curve. Cancer 70(10):2540–2546
Saijo N, Niitani H (1980) Experimental and clinical effect of ACNU in Japan with emphasis on small-cell carcinoma of the lung. Cancer Chemother Pharmacol 4:165–171
Acknowledgments
This work was supported by 2015 prior sci-tech programs of Chinese overseas talents in Beijing, and Beijing Computing Center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guo, R., Zhang, Y., Li, X. et al. Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening. J Mol Model 22, 135 (2016). https://doi.org/10.1007/s00894-016-3007-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00894-016-3007-z